The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

Richard L. Schilsky, Gary Gordon, Tona M. Gilmer, Sara A. Courtneidge, Lynn M. Matrisian, Oren Grad, William G Nelson

Research output: Contribution to journalArticle

Abstract

The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

Original languageEnglish (US)
Pages (from-to)5685-5691
Number of pages7
JournalClinical Cancer Research
Volume14
Issue number18
DOIs
StatePublished - Sep 15 2008

Fingerprint

Translational Medical Research
Biological Products
Antineoplastic Agents
Pharmaceutical Preparations
National Cancer Institute (U.S.)
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics). / Schilsky, Richard L.; Gordon, Gary; Gilmer, Tona M.; Courtneidge, Sara A.; Matrisian, Lynn M.; Grad, Oren; Nelson, William G.

In: Clinical Cancer Research, Vol. 14, No. 18, 15.09.2008, p. 5685-5691.

Research output: Contribution to journalArticle

Schilsky, Richard L. ; Gordon, Gary ; Gilmer, Tona M. ; Courtneidge, Sara A. ; Matrisian, Lynn M. ; Grad, Oren ; Nelson, William G. / The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics). In: Clinical Cancer Research. 2008 ; Vol. 14, No. 18. pp. 5685-5691.
@article{746a9b93449b49daaabf58f013cce85f,
title = "The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)",
abstract = "The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.",
author = "Schilsky, {Richard L.} and Gary Gordon and Gilmer, {Tona M.} and Courtneidge, {Sara A.} and Matrisian, {Lynn M.} and Oren Grad and Nelson, {William G}",
year = "2008",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1265",
language = "English (US)",
volume = "14",
pages = "5685--5691",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

AU - Schilsky, Richard L.

AU - Gordon, Gary

AU - Gilmer, Tona M.

AU - Courtneidge, Sara A.

AU - Matrisian, Lynn M.

AU - Grad, Oren

AU - Nelson, William G

PY - 2008/9/15

Y1 - 2008/9/15

N2 - The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

AB - The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

UR - http://www.scopus.com/inward/record.url?scp=53249111807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249111807&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1265

DO - 10.1158/1078-0432.CCR-08-1265

M3 - Article

VL - 14

SP - 5685

EP - 5691

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -